Concerning the timing of cabergoline administration, a recent retrospective study compared dosing at time of GnRH agonist versus day of retrieval with the former group exhibiting less mild-to-moderate OHSS [68]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.